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ABSTRACT 
BACKGROUND:  
Smoking is an important risk factor for chronic periodontitis (ChP), that induces 
oxidative stress in the body resulting in an imbalance between Reactive Oxygen 
Species (ROS) and antioxidants. Use of antioxidant supplementations in humans as an 
adjunct to periodontal therapy is being one of the innovative strategies in periodontal 
field.. 
AIM: 
To assess the salivary dismutase levels in predicting the effectiveness of vitamin C 
supplementation in phase I therapy in smokers and non smokers with ChP. 
MATERIALS AND METHODS: 
In the present study, a total of 70 male subjects were included, among them 10 were 
periodontally healthy controls (group I), remaining 60 subjects with chronic 
periodontitis were divided into two groups, Group II non-smokers with chronic 
periodontitis and Group III smokers with chronic periodontitis consisting of 30 
subjects in each group. Group II and group III were further divided based on the 
interventional treatment provided. Subjects treated with SRP alone were designated as 
group IIA and group IIIA and those treated with SRP and adjunct vitamin C were 
designated as group IIB and group IIIB. The salivary SOD levels were measured at 
baseline and after one month of treatment using spectrophotometry. 
RESULTS: 
Baseline salivary SOD level was significantly less in smokers than non-smokers with 
ChP as compared to control group. There was a significant reduction in all clinical 
parameters in smokers and non-smokers with ChP one month following SRP. Salivary 
SOD level significantly increased (p<0.01) in smokers and non-smokers with ChP 
one month following SRP supplemented with vitamin C. 
CONCLUSION: 
Adjunctive dose of vitamin C has improved salivary SOD level in smokers and 
non-smokers with chronic periodontitis than SRP alone. Further longitudinal studies 
may be needed for the administration of vitamin C as an adjunct to periodontal 
therapy in order to maintain a stable periodontium.  
 
 Key words: Superoxide Dismutase, Vitamin C, Chronic Periodontitis 
 
 
     DECLARATION 
 
 
TITLE OF DISSERTATION Evaluation of effectiveness of vitamin C 
following phase I therapy by estimating 
salivary superoxide dismutase level in 
smokers with chronic periodontitis.  
PLACE OF STUDY Tamil Nadu Government Dental College & 
Hospital, Chennai-600003. 
DURATION OF THE COURSE 3 Years 
NAME OF THE GUIDE Dr.S Kalaivani 
HEAD OF THE DEPARTMENT Dr.K.Malathi 
 
 
 
I hereby declare that no part of the dissertation will be utilized for gaining 
financial assistance/any promotion without obtaining prior permission of the 
Principal, Tamil Nadu Government Dental College & Hospital, Chennai-
600003. In addition, I declare that no part of this work will be published either 
in print or in electronic media without the guide who has been actively 
involved in dissertation. The author has the right to reserve for publish of work 
solely with the prior permission of the Principal, Tamil Nadu Government 
Dental College & Hospital, Chennai-600003. 
 
 
 
 Head of the Department   Guide       Signature of the candidate 
 
TRIPARTITE AGREEMENT 
This agreement herein after the “Agreement” is entered into on this day “ --------------- 
between the Tamil Nadu Government Dental College and Hospital represented by its 
Principal having address at Tamil Nadu Government Dental College and Hospital, 
Chennai – 600 003, (hereafter referred to as, „the college‟) 
And 
Dr. S. Kalaivani aged 56 years working as Professor in Department of Periodontics 
at the college, having residence address  No: 13 Mother Teresa street, Srinagar 
colony, Thirumullaivoyal, Chennai – 62 (herein after referred to as the „Principal 
Investigator‟) 
And 
Dr. K. Kirupa aged 27 years currently studying as Post Graduate student in 
Department of Periodontics, Tamil Nadu Government Dental College and Hospital, 
Chennai – 600 003, (hereafter referred to as „the PG student and co-investigator‟) 
Whereas the PG student as part of her curriculum undertakes to research on 
“EVALUATION OF EFFECTIVENESS OF VITAMIN C FOLLOWING 
PHASE I THERAPY BY ESTIMATING SALIVARY SUPEROXIDE 
DISMUTASE LEVEL IN SMOKERS WITH CHRONIC PERIODONTITIS"  
for which purpose the Principal Investigator and the college shall provide the requisite 
infrastructure based on availability and also provide facility to the PG student as to the 
extent possible as a Co – investigator 
Whereas the parties, by this agreement have mutually agreed to the various issues 
including in particular the copyright and confidentiality issues that arise in this regard. 
Now this agreement witnessed as follows 
1. The parties agree that all the Research material and ownership therein shall 
become the vested right of the college, including in particular all the 
copyright in the literature including the study, research and all other 
related papers. 
2. To the extent that the college has the legal right to do go, shall grant to 
licence or assign the copyright so vested with it for medical and/or 
commercial usage of interested persons/ entities subject to a reasonable 
terms/ conditions including royalty as deemed by the college. 
3. The royalty so received by the college shall be shared equally by all the 
three parties. 
4. The PG student and Principal investigator shall under no circumstances 
deal with the copyright, Confidential information and know – how – 
generated during the course of research/study in any manner whatsoever, 
while shall sole west with the college. 
5. The PG student and Principal investigator undertake not to divulge (or) 
cause to be divulged any of the Confidential information or, know – how  
to anyone in any manner whatsoever and for any purpose without the 
express written consent of the college. 
6. All expenses pertaining to the research shall be decided upon by the 
Principal investigator/ Co-investigator or borne sole by the PG student. 
(Co-investigator) 
7. The college shall provide all infrastructure and access facilities within and 
in other institutes to the extent possible. This includes patient interactions, 
introductory letters, recommendation letters and such other acts requires in 
this regard. 
8. The Principal Investigator shall suitably guide the Student Right from 
selection of the Research Topic  and Area till its completion. However the 
selection and conduct of research, topic and area of research by the student 
researcher under guidance from the Principal Investigator shall be subject 
to the prior approval, recommendations and comments of the Ethical 
Committee of the College constituted for the purpose. 
9. It is agreed that as regards other aspects not covered under this agreement, 
but which pertain to the research undertaken by the PG student, under the 
guidance from the Principal Investigator, the decision of the college may 
be binding and final. 
10. If any dispute arises as to the matters related or connected to this 
agreement herein, it shall be referred to arbitration in accordance with the 
provisions of the Arbitration and Conciliation Act, 1996. 
 
In witness whereof the parties hereinabove mentioned have on this day 
month and year herein above mentioned set their hands to this agreement 
in the presence of the following two witnesses. 
 
 
 
College represented by its Principal                               PG Student 
 
 
Witness        Student Guide 
 
1. 
 
                   2.  
  
 
  
S.No.             TITLE                                                                         Page No. 
                                                                             
1. INTRODUCTION                                                                         1 
2. AIM AND OBJECTIVES                                                             3 
3. REVIEW OF LITERATURE                                                       4 
4. MATERIALS AND METHODS                                                 16 
5. STASTISTICAL ANALYSIS                                                      35       
6. RESULTS                                                                                      38 
7. DISCUSSION                                                                                68 
8. SUMMARY AND CONCLUSION                                             72 
9. BIBLIOGRAPHY                                                                         73 
10.  ANNEXURES                                                                              81 
 
 
CONTENTS 
  
S. No. Title Page No 
1. Healthy Controls 30 
2. Generalized Chronic Periodontitis 30 
3. Orthopantamogram 30 
4. Armamentarium for Clinical Examination & Sample Collection 31 
5. Clinical Examination using Williams periodontal probe 31 
6. Salivary Samples 31 
7. Centrifuge machine 32 
8. Reagents for Enzyme Analysis 32 
9. Spectrophotometer 32 
10. Micropipette 33 
11. Armamentarium for phase I therapy 33 
12. Phase I Therapy 33 
13. Before  Phase I Therapy 34 
14. After  Phase I Therapy 34 
 
   LIST OF PHOTOGRAPHs 
S.No. Table Page 
Number 
1.  Master Chart 1 Group I (Control) 41 
2.  Master Chart 2 Group IIA (Non Smokers- SRP alone) 41 
3.  Master Chart 3 Group IIB (Non Smokers- SRP+ Vitamin C) 42 
4.  Master Chart 4 Group IIIA (Smokers- SRP alone) 43 
5.  Master Chart 5 Group IIIB (Smokers- SRP + Vitamin C) 44 
6.  Comparison Of Age Between Group I,II And III 45 
7.  Comparison Of Plaque Index Between Group I, II And III 45 
8.  Comparison Of Clinical Parameters And Salivary SOD Level 
Between Group I, II And III 
45 
9.  Comparison Of Clinical Parameters And Salivary SOD Level 
Between Group II And III 
46 
10.  Comparison Of Clinical Parameters And Salivary SOD Level 
Between Group II-A  And Group II-A1 
46 
11.  Comparison Of Clinical Parameters And Salivary SOD Level 
Between Group II-B  And Group II-B1 
46 
12.  Comparison Of Clinical Parameters And Salivary SOD Level 
Between Group III-A  And Group III-A1 
47 
13.  Comparison Of Clinical Parameters And Salivary SOD Level 
Between Group III-B  And Group III-B1 
47 
14.  Comparison Of Salivary SOD Level  Between  Group II-A1 And 
Group II-B1 
47 
LIST OF TABLES 
 15.  Comparison Of Salivary SOD Level Between  Group III-A1 And 
Group III-B1 
48 
16.  Comparison Of Clinical Parameters And Salivary SOD Level 
Between Group I  And Group II-A1 
48 
17.  Comparison Of Clinical Parameters And Salivary SOD Level 
Between Group I And Group II-B1 
48 
18.  Comparison Of Clinical Parameters And Salivary SOD Level 
Between Group I And Group III-A1 
49 
19.  Comparison Of Clinical Parameters And Salivary SOD Level 
Between Group I  And Group III-B1 
49 
20.  Correlation Between The Salivary SOD  Level And The Clinical 
Parameters Of Group I, II And III 
50 
21.  Correlation Between The Salivary SOD Level And The Clinical 
Parameters Of Group I, II And III 
50 
Sn
No 
FIGURES Page 
No 
1.  SOD Structure 8 
2.  SOD Standard Curve 29 
3.  Comparison of Age (in years) between Group I , Group II and Group 
III 
51 
4.  Comparison of Plaque Index between Group I , Group II and Group 
III 
51 
5.  Comparison of Gingival Bleeding Index between Group I , Group II 
A, Group II B , Group III A and Group III B 
52 
6.  Comparison of Probing Depth(in mm)  between Group I ,GroupIIA, 
Group II B, Group III A and Group III B 
52 
7.  Comparison of Clinical Attachment Level (in mm) between Group I 
, Group II A , Group II B, Group III A and Group III B 
53 
8.  Comparison of SOD Levels between Group I , Group II A, Group II 
B, Group III A and Group III B 
53 
9.  Correlation Of Salivary SOD Levels And Gingival Bleeding Index 
In Group I 
54 
10.  Correlation Of Salivary SOD Levels And Probing Depth in Group I 54 
11.  Correlation Of Salivary SOD Levels And Clinical Attachment Level 
In Group I 
55 
12.  Correlation Of Salivary SOD Levels And Gingival Bleeding Index 
In  Group II A (Pre therapy) 
55 
13.  Correlation Of Salivary SOD Levels And Probing Depth In Group II 
A (Pre therapy) 
56 
14.  Correlation Of Salivary SOD Levels And Clinical Attachment Level 
In  Group II A (Pre therapy) 
56 
15.  Correlation Of Salivary SOD Levels And Gingival Bleeding Index 
In Group II B (Pre therapy) 
57 
LIST OF FIGURES 
16.  Correlation Of Salivary SOD Levels And Probing Depth In Group II 
B (Pre therapy) 
57 
17.  Correlation Of Salivary SOD Levels And Clinical Attachment Level 
In Group II B (Pre therapy) 
58 
18.  Correlation Of Salivary SOD Levels And Gingival Bleeding Index 
In Group III A(Pre therapy) 
58 
19.  Correlation Of Salivary SOD Levels And Probing Depth In Group 
III A (Pre therapy) 
59 
20.  Correlation Of Salivary SOD Levels And Clinical Attachment Level 
In Group III A (Pre therapy) 
59 
21.  Correlation Of Salivary SOD Levels And Gingival Bleeding Index 
In Group III B (Pre therapy) 
60 
22.  Correlation Of Salivary SOD Levels And Probing Depth In Group 
III B (Pre therapy) 
60 
23.  Correlation Of Salivary SOD Levels And Clinical Attachment Level 
In Group III B (Pre therapy) 
61 
24.  Correlation Of Salivary SOD Levels And Gingival Bleeding Index 
In Group II A (Post therapy) 
61 
 
25.  Correlation Of Salivary SOD Levels And Probing Depth In Group II 
A  (Post therapy) 
62 
26.  Correlation Of Salivary SOD Levels And Gingival Bleeding Index 
In Group II A (Post therapy) 
62 
27.  Correlation Of Salivary SOD Levels And Gingival Bleeding Index 
In Group II B (Post therapy) 
63 
28.  Correlation Of Salivary SOD Levels And Probing Depth In Group II 
B  (Post therapy) 
 
63 
29.  Correlation Of Salivary SOD Levels And Clinical Attachment Level 
In Group II B (Post therapy) 
 
64 
30.  Correlation Of Salivary SOD Levels And Gingival Bleeding Index 
In Group III A (Post therapy) 
64 
31.  Correlation Of Salivary SOD Levels And Probing Depth In Group 
III A  (Post therapy) 
65 
 32.  Correlation Of Salivary SOD Levels And Clinical Attachment Level 
In Group III A (Post therapy) 
65 
33.  Correlation Of Salivary SOD Levels And Gingival Bleeding Index 
In Group III B (Post therapy) 
66 
34.  Correlation Of Salivary SOD Levels And Probing Depth In Group 
III B  (Post therapy) 
66 
35.  Correlation Of Salivary SOD Levels And Clinical Attachment Level 
In Group III B (Post therapy) 
67 
  
8-OHdG 8-hydroxydeoxyguanosine 
AAP American Academy of Periodontology 
AO Antioxidant   
CAL Clinical Attachment Level 
CEJ Cemento -Enamel Junction 
ChP Chronic Periodontits 
fMLP Formyl-Methionyl-Leucyl-Phenylalanine 
GBI Gingival Bleeding Index 
GCF Gingival Crevicular Fliud 
GPx Glutathione Peroxidase 
H2O2 Hydrogen Peroxide 
MDA Malondialdehyde 
NSPT Non-Surgical Periodontal Therapy 
O2 Oxygen 
O2
* 
Superoxide Ion 
PI Plaque Index 
PMN Polymorphonuclear leukocytes  
PPD Pocket Probing Depth 
ROS Reactive Oxygen Species 
 
ABBREVIATIONS 
SOD SuperOxide Dismutase 
SRP Scaling and Root Planing 
TAOC Total Antioxidant Capacity 
TNF Tumor Necrosis Factor 
 
 
1 
 
INTRODUCTION 
           Smoking is a harmful habit which has its existence right from 16
th
 century. 
Next to microorganisms, smoking has been considered as the strongest modifiable 
risk factor of periodontal disease with about 2 to 8 fold increase risk for attachment 
loss and bone loss
15
. Cigarette smoke not only has enormous free radicals but it also 
induces production of Reactive Oxygen Species (ROS) and depletion of antioxidants 
in tissues leading to oxidative stress and ultimately resulting in tissue damage. 
           Superoxide Dismutase (SOD) is a key antioxidant enzyme that specifically 
scavenges free radicals of oxygen. It is present in all tissues and body fluids including 
saliva 
39
. Free radicals from cigarette smoke has a tendency to attack antioxidant 
enzyme (AO) than non-enzymatic form
 12
.  
 Chronic periodontitis is an inflammatory disease wherein one of the 
mechanisms of periodontal tissue destruction involves over production of ROS and 
depletion of AO like SOD. To overcome this imbalance in the equilibrium of ROS 
and AO a supplemental antioxidant can be a possible therapeutic modality. 
           Vitamin C is a scavenging and preventing AO which is capable of regenerating 
other antioxidants
56. 
 Many studies have shown association between smoking and 
vitamin C
50,63
 and also periodontal disease and vitamin C
10,44,60
 
 Recently saliva has gained more attention as a diagnostic fluid. Whole saliva 
represents a pooled sample with contributions from all periodontal sites, analysis of  
biomarkers in saliva may provide an overall assessment of disease status as opposed 
to site – specific GCF analysis.58  For this reason, the levels of several enzymes, 
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proteins and other constituents of saliva have been investigated for possible 
correlation with periodontal disease activity
24
.  
  So far very few interventional studies have been conducted regarding the 
effect of non-surgical periodontal therapy supplemented with antioxidants on SOD 
levels. 
Hence the aim of the present study is to estimate salivary SOD levels in 
smokers with chronic periodontitis and to ascertain the effectiveness of vitamin C 
supplementation following phase I therapy. 
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AIM 
To assess the salivary dismutase levels in predicting the effectiveness of vitamin C 
supplementation in phase I therapy in smokers and non smokers with chronic 
periodontitis. 
OBJECTIVES 
1. To compare salivary SOD levels in smokers/nonsmokers with chronic periodontitis  
2. To compare salivary SOD levels before and after phase I therapy in the same 
subjects. 
3. To evaluate the effectiveness of vitamin C therapy as an adjunct to phase I therapy. 
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REVIEW OF LITERATURE 
  Periodontal diseases are inflammatory disorders that give rise to tissue injury 
and loss, as a result of the complex interactions between pathogenic bacteria and the 
host immune response.
20
 It is likely that the role of reactive oxygen species (ROS) is 
common to both bacterial and host-mediated periodontal tissue damage. Recently the 
role of ROS in the pathogenesis of periodontitis has gained more attention.  
SALIVA-DIAGNOSTIC MEDIUM: 
 Saliva is a secretion of the salivary glands, ensures stability in the oral cavity 
environment. “Whole saliva” is composed of saliva , gingival crevicular fluid 
contained in the dento-gingival sulcus, transudate, cell detritus, bacteria and food 
debris.
9
 For periodontal diagnosis,  use of saliva has been the subject of considerable 
research activity, and  has proposed markers for disease including proteins of host 
origin (i.e. enzymes, immunoglobulins), host cells, hormones (cortisol), phenotypic 
markers (epithelial keratins), bacteria and bacterial products, volatile ions and 
compounds
47
. Enzymes present in saliva may be of host derived (cells in the salivary 
glands, PMNs, epithelial cells, and from GCF) or from microorganisms
19
. The 
correlation between its biomarkers and clinical features of periodontal disease has 
been evaluated for the following aspects of periodontitis – inflammation, collagen 
degradation and bone turnover. 
 For the past two decades, salivary diagnostic approaches are developed to 
monitor periodontal diseases
24
, to assess caries risk
16
, and to diagnose oral cancer
45
. 
Recently, due to emerging biotechnologies in salivary diagnostics, a large number of  
analytes in saliva are gradually unveiled, some of them represent biomarkers for 
different diseases including cancer, infections, etc
23
. The most challenging part of 
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salivary diagnostics is to identify disease markers and effectively translate the 
research efforts from the laboratory to the clinic. 
  Nieminen et al
54
 stated that the enzyme activity of whole saliva likely reflects 
the periodontal disease severity, and salivary enzymes have the potential to assess 
periodontal inflammation and its response to periodontal treatment.  
SUPER OXIDE ION - REACTIVE OXYGEN SPECIES (ROS): 
 In 1769  Fridovich  showed that superoxide ion was produced during an 
enzymatic oxidation. Superoxide is being formed by addition of an extra electron to 
the oxygen molecule. 
 Battino M et al
14
 in 1999 made a remarkable expansion in medical and dental 
field concerned with free radicals, ROS and AO defense mechanism. 
Sources of superoxide: 
1.Exogenous sources:  
Include heat, ultraviolet light, ozone, trauma, ultrasound, radiation, smoking, 
exhaust fumes, infection, excessive exercise, and therapeutic drugs
27
 
2. Endogenous sources are primarily: 
• Byproducts of metabolic oxidative pathways – electron leakage from 
mitochondrial electron transport systems leads to formation of superoxide
39 
• Functional generation by  activated phagocytes such as PMNLs through 
“respiratory burst”25 and cells like fibroblasts52.  
ASSOCIATION OF BETWEEN SMOKING AND ROS IN PERIODONTITIS: 
 Smokers are exposed to over 40,000 chemicals from cigarette smoke and the 
combustion of tobacco creates almost 1 x 10 free radicals per cigarette [5x10 per puff] 
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 Smoking disturbs neutrophil chemotaxis or phagocytosis
28
 and stimulates 
oxidative burst
61
, increases the number of neutrophils found in systemic circulation, 
increase their formyl-methionyl-leucyl-phenylalanine (fMLP) receptors and leaving 
them “primed”, which results in a two-fold increase in the release of elastase and 
superoxide ion in response to fMLP
59
. Neutrophils express functional receptors for 
several components and metabolites of tobacco  like nicotine, cotinine (α3, β4 subtype 
of nicotine   receptors) 
61 
In animal and human studies, cigarette smoke has been found to affect both  
cell mediated and humoral immunity
40,68
. Nicotine inhibits antibody forming cell 
responses leading to  immunosuppression that appears to be due to the effect of 
impairment of antigen mediated T cell signalling
68
 Studies by Hughes et al in. 1985, 
showed leukocytosis in smokers
38 
  An increased priming effect of TNF-α has also been shown in smokers with 
periodontitis accompanied by an increased generation of free radicals and up-
regulated neutrophil function
34
 Gillespie et al.
 30 
in 1987, showed a potentiated release 
of superoxide ion from neutrophils in rats exposed to smoke.  
 There is convincing evidence that the antioxidant status of smokers is reduced. 
Cigarette smoke may result in an increased metabolic turnover, because of greater 
expenditure of antioxidant micronutrients from increased oxidative stress that is 
caused by the tobacco products, or smoking could decrease micronutrient absorption
7
. 
In contrary it has also been revealed that the antioxidant response may be 
overwhelmed as a protective mechanism counteracting the harmful effects of ROS.
72
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ASSOCIATION BETWEEN SMOKING AND PERIODONTITIS: 
Stolenberg J.L. et al
70
 in 1993 concluded that smoking is a stronger risk 
indicator for the mean posterior proximal probing depth 3.5mm.
 
Kinane D.F. et al
43
. in 1997 evaluated the effect of smoking on the outcome 
of periodontal therapy and stated that smoking has a negative effect on the prognosis 
of periodontal treatment mainly in persistent and deep pockets. 
Bergstrom et al
15
 in 2000 reported that heavy exposure to cigarette smoke 
was consistently associated with more severe condition than light exposure, signifying 
that the relationship between smoking  and periodontal morbidity is dose-dependent 
and an avoidable risk factor for periodontal disease.
 
Nair P. et al
53 
in 2003 emphasized on the effect of smoking in masking the 
signs and symptoms of inflammatory process and the reversible effect on quitting 
smoking.
 
Darby IB et al
26
 in 2005  concluded that SRP was effective in reducing the 
severity of clinical parameters  but an inferior improvement in smokers which was 
due to the systemic effects of smoking on the host response and in healing process. 
Wan CP et al
73
 in 2009 investigated the factors predicting responses of non-
surgical periodontal treatment by multilevel multiple regressions and found that 
smokers showed less favourable probing depth reduction at deep sites.
 
ANTIOXIDANT DEFENSE SYSTEMS  
 To counteract the harmful effects of ROS, a number of antioxidant defense 
mechanism exists. Halliwell
36
 in 1994 defined  antioxidant  as “any substance that 
when present at low concentrations compared to those of an oxidisable substrate, 
significantly delays or inhibits the oxidation of the substrate” 
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 Antioxidants (AO‟s) are classified according to their mode of action as follows: 
1. Preventive antioxidants: Catalase, SOD, Carotenoids, Transferrin, 
Ceruloplasmin, 
2. Radical scanvenging: Ubiquionol, Vitamin A, Vitamin E, Carotenoid, Uric 
acid, ascorbic acid, albumin, Bilirubin 
3. Repair and de-novo enzymes: DNA  repair enzymes, protease, transferase, 
lipase
21
 
SUPEROXIDE DISMUTASE ENZYME 
 Superoxide dismutase (SOD) is a metalloenzyme and its main active centre is 
occupied by copper and zinc, manganese or iron. SOD plays an important role in the 
protection of all aerobic lives, including man, against oxygen toxicity and the free 
radicals derived from oxygen. 
Joe M. McCord
39
 in 1969 analysed the abundance of SOD activity in animal 
tissue and suggested that SOD might play a significant role in protecting the 
organisms from the damaging effects of superoxide radical.
 
McCord JM
48
 in 1978 
stated that "SOD exerts an anti-inflammatory action that may be useful in managing 
inflammation". 
Figure 1 : Structure of Superoxide Dismutase 
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 SOD catalyses the conversion of O2
•-
 to H2O2 via a dismutation reaction 
Superoxide dismutase uses one O2
•-
 radical to oxidize another. 
  2O2
*
 + O2
*
 + 2H 
+
  H2O2+ O2  
 There are three forms of superoxide dismutase in mammalian tissues, each 
with a specific sub-cellular location and different tissue distribution. 
1. Copper zinc superoxide dismutase (Cu/ZnSOD): It is found in the cytoplasm. In     
humans, Cu/Zn SOD is assumed to play a major role in the first line of AO defense. 
2. Manganese superoxide dismutase (Mn-SOD): It is found in mitochondria.  
3. Extracellular superoxide dismutase (EC-SOD): It was described by Marklund in 
1982. It is synthesized by few cell types, like fibroblasts and endothelial cells, and 
expressed on the cell surface where it is bound to heparin sulphates. 
Sculley and Langley-Evans
64
 in 2003 examined the antioxidant conditions in 
the saliva and reported that gingivitis and periodontitis were associated with a 
decreased salivary antioxidant level and increased oxidative injury. They also 
reported that low concentrations of GCF antioxidants increase the neutrophil-induced 
injuries in the gingiva.
 
Akalin FA et al
5
 in 2005 compared SOD activities in gingiva and GCF from 
patients with ChP and periodontally healthy controls. In ChP, SOD activity appears to 
increase in gingiva, possibly as a result of a higher necessity for SOD activity and 
protection in gingiva in ChP, while not changed significantly in GCF, which suggest a 
weak SOD activity in GCF.
 
Baltacioglu et al
13
 in 2006
 
 compared the serum and GCF total antioxidant 
capacity (TAOC) and SOD concentrations in post-menopausal and pre menopausal 
____________________________________________________________________Review of Literature 
 
10 
 
women with ChP. Results showed that serum and GCF TAOC and SOD 
concentration were significantly lower in menopause and ChP subjects. 
Akalin FA
4
 in 2009 compared serum and gingival crevicular fluid (GCF) total 
AO capacity (TAOC) and SOD concentrations in pregnant patients with ChP with 
non-pregnant patients. TAOC and SOD levels were lowest in the pregnant patients 
with ChP group in the third trimester (P <0.05).
 
 Canakci et al
18
 in 2009 evaluated 8-hydroxydeoxyguanosine, Malondialdehyde 
levels, superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities in 
whole saliva of patients with chronic periodontitis. Their findings showed a higher 8-
OHdG and MDA levels in saliva and lower salivary SOD and GPx activities in ChP 
patients compared to the periodontally healthy controls.
 
Kim et al
42
 in 2010 compared the total antioxidant status (TAS) and superoxide 
dismutase (SOD) activity in the saliva of ChP patients before and after scaling and 
root planing. The SOD activity in the test subjects decreased immediately after SRP 
until 1 month. At 3 months after SRP, the SOD activity had increased.  
ASSOCIATION BETWEEN SMOKING AND SOD: 
Gururaj et al
33
 in 2004 estimated the antioxidants in oral exfoliated cells. Their 
findings showed that both the glutathione reductase and SOD enzyme activities in the 
exfoliated cells were significantly higher in the non smoker group as compared to 
smokers. The reduction in the level of AO in smokers may be due to tobacco smoke 
induced free radical liberation. This indicates that in smokers, the cells are under 
oxidative stress and damage.  
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Kanehira et al
41 
in 2006
 
 measured the salivary SOD level of smokers and 
concluded that measurement of SOD in saliva might be used to estimate the level of 
oxidative stress on smoking habits
 
Garg et al
29
 in 2006 evaluated the association between smoking and periodontal 
damage in terms of free radicals and antioxidant levels. They concluded that SOD 
levels were higher in non-smokers with ChP than smokers with ChP both in tissue and 
blood. They concluded that smoking increases free radicals level in periodontal 
tissues, which in turn may be reason for the destruction seen in periodontal disease.
 
Buduneli N et al
17
 in 2006 evaluated possible effects of smoking and gingival 
inflammation on antioxidants in saliva in gingivitis patients. They concluded neither 
smoking nor gingival inflammation affected the salivary antioxidant capacity in 
systemically healthy gingivitis patients. 
 Agnihotri R et al
2
 in 2009 assessed the influence of smoking on the 
periodontium by estimating the levels of SOD in light and heavy smokers with 
periodontitis in saliva and GCF. The findings showed that the SOD level in GCF and 
saliva of smokers were decreased compared to periodontally healthy controls. Their 
study also showed a progressive reduction in SOD levels in healthy controls to light 
smokers to heavy smokers, signifying that increased oxidative stress and nicotine in 
smokers had resulted in the depletion of antioxidant enzymes
 
Pasupathi et al
57
 in 2009 determined the effect of cigarette smoking on changes 
in lipid profile, lipid peroxidation and antioxidant status in smokers. Biochemical 
parameters such as cardiac markers, lipid profile, and antioxidants like SOD, catalase, 
glutathione peroxidase, vitamin A, C and E were also measured. The findings showed 
that there was a significant increase in levels of cardiac markers, but a huge depletion 
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of antioxidants in smokers as compared to non smokers. The researchers concluded 
that the atherogenic effects of smoking are mediated  partly  by free radical damage to 
lipids and  breakdown of antioxidant status in cigarette smoking
. 
Hamid-reza Abdolsamadi et al
37
 in 2011 compared the salivary antioxidant 
levels  between healthy smoking and non-smoking men. The mean levels of salivary 
superoxide dismutase and glutathione peroxidase were significantly lower in smokers 
than non-smokers. Measurement of antioxidant agents in saliva might be useful for 
estimating the level of oxidative stress caused by smoking.
 
VITAMIN C - AN ANTIOXIDANT: 
 Vitamin C is a chain-breaking antioxidant that has anticarcinogenic and 
immunomodulatory actions. This antioxidant has to be supplemented only through 
diet as human cells cannot generate vitamin C. 
 In 1747 James Lind conducted  experiments aboard the ship „„the Salisbury‟‟ 
in which he cured scurvy with lemons and oranges
71
Meyle and Kapitza
49
 in 1990 
reported that levels of vitamin C in GCF is 3 times higher than plasma. Sagan et al
62 
in 2005 suggested that dietary vitamin C enters the mitochondria of the cell and 
protects against oxidative injury.
 
Possible etiologic relationships between ascorbic acid and periodontal disease.  
1. Ascorbic acid deficiency may lead to 
 1. Impairment in regeneration and repair of periodontal tissue due to  
 impairment in the collagen metabolism. 
2. Interferes with bone formation, leading to loss of periodontal bone.  
3. Increases the permeability of the oral mucosa to endotoxin and 
inulin and of normal human crevicular epithelium to dextran. 
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4. May interfere with the ecologic equilibrium of bacteria in plaque and thus 
increase its pathogenicity 
2. Increasing levels of vitamin C enhance both the chemotactic and migratory action 
of leukocytes (neutrophils) without influencing their phagocytic activity 
3. An optimal level of vitamin C is apparently required to maintain the integrity of the 
periodontal microvasculature; and the vascular response to bacterial irritation and 
wound healing.
19 
Chapple 
21
 in 2007 summarized its role as an antioxidant:
 
• Scavenging water-soluble peroxyl radicals. 
• Scavenging superoxide and perhydroxyl radicals. 
• Prevention of damage mediated by hydroxyl radicals on uric acid. 
• Scavenger of hypochlorous acid. 
• Preventing Fenton reactions. 
• Scavenger of singlet oxygen and hydroxyl radicals. 
• Re-forms a-tocopherol from its radical. 
• Protects against ROS-release from cigarette smoke.  
Association between vitamin C and smoking 
Schectman, et al
63
 in 1989 conducted a study to define the independent 
relationship between smoking and vitamin C status. The association of smoking with 
serum vitamin C levels was analyzed. The author concluded an inverse relation exists 
between smoking and dietary vitamin C intake. This confirms that smokers have 
lower concentrations of vitamin C in serum than non-smokers.
 
Mieko Nishida et al
50
 in 2000 evaluated the role of dietary vitamin C as a risk 
factor for periodontal disease utilizing Third National Health and Nutrition 
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Examination Survey. The authors concluded that dietary intake of vitamin C  showed 
a weak, but  a significant, relationship to periodontal disease in former and current 
smokers as measured by clinical attachment level.
 
Greabu et al
32
 in 2007 studied the effect of vitamin C on salivary antioxidants 
and showed that cigarette smoke decreases uric acid level in saliva. Addition of 
10mg/dl vitamin C to saliva was not able to restore the original uric acid level but it 
significantly increased uric acid level. This implies, vitamin C has a protective effect 
on uric acid level in saliva. They suggested that an adequate amount of antioxidant 
intake may help smokers to overcome cigarette smoke-induced oxidative damage.
 
Bakhtiari Sedighe et al
12
 in 2011 performed a study to elucidate the effect of 
vitamin C on salivary superoxide dismutase (SOD) activity in smokers and concluded 
that vitamin C does not improve SOD activity significantly. It is possible that smoke–
induced oxidative stress might decrease after vitamin C intake.
 
ROLE OF VITAMIN C IN PERIODONTAL THERAPY: 
        Leggot et al
44
 in 1986 conducted a study to determine whether systemic levels 
of vitamin C influence periodontal health, by measuring PI gingival health and PD  in 
healthy subjects who were provided controlled periods of ascorbic acid depletion and 
supplementation for three months. No changes in PI or PD were found during any of 
the periods of depletion or supplementation. But gingival inflammation measurements 
were directly related to the ascorbic acid status. The finding suggest that vitamin C 
may influence early stages of gingivitis, principally crevicular bleeding.
 
Pussinen et al
60
 2003 in studied the relationship between periodontitis and the 
concentration of ascorbic acid in serum. They reported that patients with periodontitis, 
who were infected by P. gingivalis, showed a lower ascorbic acid level in the serum 
than those not infected.
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Staudte H et al
69
 in 2005 examined the plasma vitamin C levels and 
inflammatory parameters in periodontitis patients before and after taking grape fruit. 
The intake of grape fruit resulted in an increase in plasma vitamin C levels and 
improved sulcus bleeding scores. 
Amaliya et al
10
 in 2007 conducted a study, comparing the relationship between 
vitamin C and the severity of periodontitis. They observed negative correlation  
between plasma vitamin C level and periodontal attachment loss (p<0.05). This 
suggests that vitamin C deficiency may contribute to the periodontal breakdown.
 
Ali E et al
8
 in 2010 investigated plasma total antioxidant capacity in patients with 
ChP and assessed the effects of vitamin C as an adjunct to phase I therapy. The author 
observed that ChP was significantly associated with lower levels of plasma TAOC. 
Phase I therapy had reduced the oxidative stress during the periodontal inflammation. 
But no improvement with vitamin C supplementation was noted. However, the use of 
adjunctive vitamin C still needs further investigation.
 
Abdul Samed Aziz et al
1 
in 2012 evaluated and compared, following parameters 
total antioxidant capacity (TAOC), RBC-SOD,  GPx, Vitamin C, Malondialdehyde 
(MDA) and C-reactive protein (CRP) between controls and CP. Obtained results 
suggest that oxidative stress is induced in chronic periodontitis. As compared to 
periodontally healthy controls the levels of CRP, MDA and RBC-SOD were 
significantly higher (p<0.001) and those of TAOC, GPx and vitamin C were 
significantly lower (p<0.001) in patients with chronic periodontitis
 
Akmans et al
6
 in 2012 investigated the role of Alpha-Lipoic Acid (ALA) and 
Vitamin-C  in the treatment of alveolar bone resorption in periodontal diseases. The 
author evidenced that ALA and Vitamin-C treatment provided beneficial effects on 
inhibition of periodontal tissue destruction and alveolar bone resorption in rats.
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MATERIALS AND METHODS 
 Subject Selection: 
The study population consisted of 70 subjects who attended the Outpatient 
Section of the Department of Periodontics, Tamil Nadu Government Dental College 
and Hospital, Chennai, India. Ethical clearance was obtained from the Institution’s 
Ethical Committee. 
Inclusion Criteria 
 Minimum of 20 teeth present 
 35 – 60 years of age, 
 Gender – Males 
Exclusion criteria included:  
 Patients with underlying systemic diseases 
 Patient who have received medication (antibiotics, anti inflammatory, steroids, 
anxiolytics) for past 4 to 6 months. 
 History of vitamin supplements for the past 3 months. 
 Patients with other oral habits ( tobacco and pan chewing) 
 Absence of any lesions in the oral cavity, and  
 Patients who had undergone periodontal treatment in past 6 months. 
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Group I: Control Group: 
 Sample size n = 10 
 No sites with Probing Depth >3 mm  
 Less than 20% of sites exhibiting gingival bleeding. 
Group II:  Study Group- non smokers:   
Sample size n = 30 
The diagnosis of Chronic Periodontitis was established on the basis of clinical and 
radiographic criteria (bone loss) according to the AAP 1999 classification system for 
periodontal diseases and conditions
11
.  
 A minimum of six teeth with at least one site each with Probing Depth  
≥5mm and Clinical attachment level ≥1 mm, and  
 Presence of Bleeding on Probing. 
 Group II was further divided into: 
 Group II A: SRP only (n = 15) 
 Group IIA1: After therapy 
 Group II B: SRP with vitamin C supplementation (n = 15) 
 Group II B1: After therapy 
Group III: Study Group- smokers : 
 Sample size n = 30 
The diagnosis of Chronic Periodontitis was established on the basis of clinical and 
radiographic criteria (bone loss) according to the AAP 1999 classification system for 
periodontal diseases and conditions
11
.  
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 A minimum of six teeth with at least one site each with Probing Depth 
≥5mm and Clinical attachment level ≥1mm, and  
 Presence of Bleeding on Probing. 
 Smokers  
Group III was further divided into: 
 Group III A: SRP only (n = 15) 
 Group III A1: After therapy 
 Group II B: SRP with vitamin C supplementation (n = 15) 
 Group III B1: After therapy 
In addition, all subjects should meet the following criteria:  
 Should have controlled oral hygiene during periodontal treatment, 
 Agreement to participate in the postoperative control program. 
STUDY PROTOCOL 
1. Medical History and Informed Consent 
2. Complete Periodontal Examination using clinical parameters namely  
Gingival Bleeding Index, Plaque Index, Probing Pocket Depth (PPD) and 
Clinical Attachment Level (CAL) 
3. Radiographic evaluation of generalized chronic periodontitis  
4. Collection of saliva samples 
5. Appropriate treatment performed for Group II and Group III patients 
6. Re-evaluation of Group II and Group III patients using clinical parameters 
namely, Gingival Bleeding Index, Probing Pocket Depth and Clinical 
Attachment Level. 
7. Collection of saliva samples in Group II and Group III patients 1 month 
after therapy 
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8. Estimation of SOD in saliva samples by spectrophotometric analysis. 
 Subjects for the study were selected randomly, with no discrimination on the 
basis of age, caste, religion or socioeconomic status between control and study 
groups. Following selection of subjects, written informed consent (Annexure 2 & 3), 
which was approved by the Institute’s Ethical Committee, was obtained from all the 
subjects selected for the study after explaining the study procedure. Examination was 
preceded by a thorough medical and dental history of the subjects (Annexure 4). 
Each subject underwent full-mouth periodontal probing and for radiographic 
evaluation orthopantomogram was taken. Radiographic bone loss was recorded 
dichotomously (as presence or absence) to differentiate patients with periodontitis 
from other groups. Then about 2ml of unstimulated whole saliva was collected from 
the subjects for spectrophotometric analysis.   
PERIODONTAL EXAMINATION: 
CLINICAL PARAMETERS 
The following clinical parameters were evaluated for all patients: 
1. Gingival bleeding index – Ainamo and Bay  1975. 
2. Plaque index – Silness and Loe  1964 
3. Probing Pocket Depth in mm (PPD) – Carranza 10th ed  
4. Clinical attachment level in mm (CAL) – Carranza 10th ed  
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Gingival Bleeding Index (Ainamo and Bay  1975)
3
  
Starting distobuccally, the probe was inserted slightly into the sulcus and run 
to the buccal and mesial surfaces of every tooth at an angle of about 45
o
. This was 
repeated for all teeth present. Probing was similarly carried out at palatal/lingual sites. 
Any gingival units that exhibited bleeding were recorded. The total number of 
bleeding sites per tooth was thus recorded for every tooth except the third molar. 
Criteria for Scoring 
Positive score (+) - Presence of bleeding within 10 seconds  
Negative score (-) - Absence of bleeding 
    Total number of positive score 
% of bleeding sites =      x 100 
    Total number of surfaces of all teeth 
 
Plaque Index  (Silness and Loe 1964) 
67 
All teeth were examined at 4 surfaces each (disto-facial, facial, mesio-facial, 
lingual/palatal) and were scored as follows. 
Criteria for Scoring: 
Score 0 No plaque 
Score 1 Plaque not visible to the naked eye, detected by explorer 
Score 2 Thin to moderate accumulation of soft deposits within the gingival 
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pocket or on tooth, visible to the naked eye 
Score 3 Abundance of soft matter within gingival pocket or on tooth surface 
and margin, inter-dental area stuffed with soft debris 
Calculation :                                      
 Plaque index per tooth      =     Total score/4           
Plaque index per individual      ═   Total PI per tooth / Total number of teeth 
      examined 
Interpretation: 
     Score   0 –     Excellent oral hygiene 
                           0.1 to 0.9  –  Good oral hygiene 
                           1.0 to 1.9 –   Fair oral hygiene 
                           2.0 to 3.0 -   Poor oral hygiene 
Probing Pocket Depth (PPD)(In mm)(Carranza 10
th
 ed  )
19 
Probing Pocket Depth was measured from the gingival margin to the base of 
the pocket in millimeters using Williams Periodontal Probe. The probe was walked 
within the gingival sulcus along the circumference of the tooth. Six measurements 
were made per tooth (Mesiobuccal, Midbuccal, Distobuccal, Mesiolingual, 
Midlingual, and Distolingual). 
Clinical Attachment Level (CAL) (Carranza 10
th
 ed  )
19 
 Clinical Attachment Level was measured from the Cemento – Enamel 
Junction (CEJ) to the base of the pocket using Williams Periodontal Probe.  
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 When the gingival margin was located on the anatomic crown, the level of the 
attachment was determined by subtracting from the probing pocket depth, the 
distance from the gingival margin to the CEJ. If both were the same, the loss 
of attachment was calculated to be zero.  
 When the gingival margin coincided with the CEJ, the loss of attachment was 
calculated as equaling the probing pocket depth.  
 When the gingival margin was located apical to the CEJ, the loss of 
attachment was greater than the probing pocket depth and therefore the 
distance between the CEJ and the gingival margin were added to the PPD. 
Three measurements were made on the buccal aspect and three on the lingual 
aspect of each tooth – total of six sites per tooth (Mesiobuccal, Midbuccal, 
Distobuccal, Mesiolingual, Midlingual, and Distolingual).  
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ARMAMENTARIUM 
For clinical examination 
 Mouth mirror  
 Williams calibrated periodontal probe 
 Curved explorer 
 Dental tweezers 
 Kidney tray 
 Cotton roll 
 Sterilized disposable gloves  
 Disposable facemask 
For collection of saliva sample 
 Vaccutainer . 
 Sterile cotton. 
For saliva storage : 
 -20
0
 C freezer 
For SRP : 
 Mouth mirror 
 Explorer 
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 Scalers and Curettes  
 Kidney Tray 
 Cotton Rolls 
 Disposable Gloves 
 Disposable Facemask 
 Disposable Headcap 
 Disposable syringe 
 Local Anaesthetic solution 
For Enzymatic Assay 
 Diagnostic Reagent kits 
 Spectrophotometer 
 Distilled Water 
 Sterile test tubes 
 Micropipettes  
 Syringes 
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Saliva Sample Collection 
Saliva sample was collected at: 
 Baseline 
 4 weeks post treatment 
Samples of unstimulated, whole saliva was taken before and after treatment in 
empty stomach. Immediately after rinsing with water, 2ml Saliva of the patient was 
collected in vaccutainer. The saliva sample was stored at -20
0
 C
 
in bio-chemical 
laboratory and the activity of the superoxide dismutase salivary enzyme was 
determined spectrophotometrically.  
After saliva sample collection appropriate treatment was performed to each 
group. 
Group I: 
  No treatment required and kept under maintenance. 
Group IIA and IIIA:  
 Nonsurgical periodontal therapy consisting of scaling and root debridement 
done and oral hygiene instructions given. 
Group IIB and IIIB:  
  Nonsurgical periodontal therapy consisting of scaling and root debridement 
done. Oral hygiene instructions given. Vitamin C supplement 500mg OD for 4 weeks 
given. 
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Laboratory Procedure for Assessment of Superoxide Dismutase Enzyme Activity 
Principle:  
Superoxide dismutase role is to accelerate the dismutation of the toxic 
superoxide ion, produced during oxidative energy process, to hydrogen peroxide and 
molecular oxygen. The kit used for study employs xanthine and xanthine oxidase to 
generate superoxide radicals which react with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-
phenyltetrazolium chloride (I.N.T) to form a red formazan dye. 
The superoxide dismutase function is then measured by the degree of 
inhibition of the reaction. 
        
                    𝑋𝑎𝑛𝑡ℎ𝑖𝑛𝑒                    𝑥𝑎𝑛𝑡ℎ𝑖𝑛𝑒 𝑜𝑥𝑖𝑑𝑎𝑠𝑒                𝑈𝑟𝑖𝑐 𝑎𝑐𝑖𝑑 +  O2
-    
         
                INT                                       O2
-                                               
Formazan dye. 
    
                       
O2
-
   +    O2
-
   +   2H
+                   
SOD
                                    
O2  +   H2O2 
 
 
Reagent preparation: 
1.Mixed Substrate(R1): 
Reconstitute the contents of one vial of Mixed Substrate R1 with 20ml of Buffer R2. 
2.Buffer (R2): 
Content is ready to use. 
3.Xanthine oxidase (R3): 
Reconstitute the contents of one vial of R3with 10ml of distilled water. 
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4. Standards (R4): 
Reconstitute the contents of one vial of R4 with 10ml of distilled water. Subsequent 
dilutions of this standard must be with sample diluent (R5). The following dilutions 
are made of standard S6 to produce a standard curve. 
 
 Vol of standard solution Vol of sample diluent 
S6 Undiluted standard  
S5 5ml of S6 5ml 
S4 5ml of S5 5ml 
S3 5ml of S4 5ml 
S2 3ml of S3 5ml 
 
S1 = Sample Diluent 
 
5.Sample Diluent: Content ready to use. 
 
Sample : 
0.5ml of distilled water, 0.25ml ethanol and 0.15ml chloroform were added to 0.5 ml 
collected saliva, mixed in a vortex machine. Then 0.1ml of distilled water was added 
and the solution was centrifuged at 2000rpm for 15min. The supernatant was diluted 1 
in 100 times with SOD sample diluents to give diluted sample.  
 
Manual procedure: 
Wave length Temperature Cuvette Measurement 
505nm 37
0
C 1cm light path Against air 
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Pipette into test tubes as follows: 
 Sample diluent Standards S2 –S6 Diluted Sample 
Diluted Sample   50µl 
Standard   50µl  
Sample diluent 50µl   
Mixed Substrate 1.7ml 1.7ml 1.7ml 
Mix well, then add: 
Xanthine Oxidase 250µl 250µl 250µl 
 
 
The mix was incubated for 30s at 37
0
C, then first reading was taken. Readings 
were taken again after 1,2 and 3 minutes. 
To determine the mean absorbance change per min (  A) the following 
calculation was used. 
 
Calculation: 
To calculate the SOD value =  
𝐴2−𝐴1
3
   =      A/min of standard or sample  
 
For standard:                                          
100 – 
𝐴𝑠𝑡𝑑 / min 𝑥100
𝐴𝑠1/𝑚𝑖𝑛
      = %  inhibition  
 
For sample 
100 – 
𝐴𝑠𝑎𝑚𝑝𝑙𝑒 / min 𝑥100
𝐴𝑠1/𝑚𝑖𝑛
 = % inhibition 
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Plot percentage inhibition for each standard against standard conc. in SOD units/ml 
Percentage inhibition of sample was used to obtain units of SOD from standard curve. 
 
Figure 2:      Standard curve. 
 
 
 
 
SOD units/ml of whole saliva       =              SOD units/ml from standard curve  
                                                        X    dilution factor 
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Photograph 1 : Healthy Controls 
 
Photograph 2: Generalized Chronic Periodontitis 
 
 
 Photograph 3: Orthopantamogram for Chronic Periodontitis Group 
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Photograph 4: Armamentarium for Clinical Examination & Sample Collection 
 
Photograph 5: Clinical Examination using Williams periodontal probe 
 
 
Photograph 6: Salivary Samples 
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Photograph 7: Centrifuge machine 
 
Photograph 8: Reagents for SOD Enzyme Analysis 
 
 
Photograph 9: Spectrophotometer 
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Photograph 10: Micropipette 
 
 
Photograph 11: Armamentarium for phase I therapy 
 
Photograph 12: Phase I Therapy 
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Photograph 13: Before  Phase I Therapy 
 
 
 
 
 
Photograph 14: After  Phase I Therapy 
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STATISTICAL ANALYSIS 
 
 The statistical package SPSS V16 (Statistical Package for Social Science, 
Version 16) was used for statistical analysis. 
PAIRED t TEST: 
 For a comparison of more than one pair of split sample test results, the t-test for 
paired measurements can be used.  
The formula of the t-test for paired measurements is: 
 
 
 
n
s
XX
t
d
Od 

    
 
 
Where:   dX =   Average of the differences between the individual split sample test 
results 
 
OX =   The value of the expected difference between split sample tests.  In 
most cases X0=0, as there is no expected difference between 
contractor and agency tests.  However, X0 could reflect an expected 
correlation value between testing entities. 
 
ds =   Standard deviation of the differences between the split sample test 
results 
 
n   =   Number of split samples 
 
INDEPENDENT t TEST:  
To compare the statistical significance of a possible difference between the means of 
two groups on some independent variable and the two groups are independent of one 
another. The formula for the independent t-test is 
, 
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Where, 
is the mean for group 1, 
is the mean for group 2, 
is the sum of squares for group 1, 
is the sum of squares for group 2, 
n1 is the number of subjects in group 1, and 
n2 is the number of subjects in group 2. 
One-Way ANOVA: 
Computational Formulas for ANOVA 
Null Hypothesis states that H0: μ1 = μ2 = μ3 = . . . = μa  
ANOVA analyzes sample variances to draw inferences about population means. 
Sample variances can always be calculated as SS/df and these sample variances are 
called mean squares (MS). 
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Where, 
SS – Sum of Squares 
MS – Mean Squares 
N = total  no  of observations in the experiment 
a = No of groups 
n1 =  no of observations in group 1, etc. 
F = observed Variance Ratio 
tCrit is the critical value from a t-table using the df of the error term from the ANOVA 
table. F > tCrit at 5%value means that the difference between the groups is significant 
at the 5% value. 
P value: 
 The P value or calculated probability is the estimated probability of rejecting 
the null hypothesis (H0) of a study question when that hypothesis is true. Differences 
between the two populations were considered significant when p < 0.05. 
PEARSON CORRELATION: 
Pearson correlation (Bivariate) was used to analyze the strength of association 
between the investigated variables. The correlation coefficient (r) was interpreted as 
follows. 
0.0 - 0.1 - Trivial, 
0.1 - 0.3 - Low 
0.3 - 0.5 - Moderate 
0.5 - 0.7 – High 
0.7 - 0.9 - Very high 
0.9 - 1 - Nearly perfect 
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RESULTS 
In the present study, a total of 70 male subjects were included, among them 10 
were periodontally healthy controls (Group I), remaining 60 subjects with chronic 
periodontitis were divided into two groups, Group II non-smokers with chronic 
periodontitis and Group III smokers with chronic periodontitis consisting of 30 
subjects in each group. Group II and Group III were further divided into Group IIA ; 
Group IIB and Group IIIA ; Group IIIB respectively, with 15 members each, based on 
the interventional treatment provided. Subjects treated with SRP alone were 
designated as Group IIA and Group IIIA and those treated with SRP with an adjunct 
vitamin C were designated as Group IIB and Group IIIB. Subsequently the post-
treatment Groups were designated as A1 and B1 for each respective Group.  
Table 1, 2, 3, 4 and 5 represents the master chart for Group I,IIA,IIB,IIIA and 
IIIB respectively. The mean age was 42.83 (Group I- 41.5±5.77, Group II- 44.3±6.41 
and Group III -42.96±6.44) (table 6; fig.3). 
CLINICAL FINDINGS: 
 The clinical parameters used were plaque index (PI), gingival bleeding index 
(GBI), pocket probing depth (PPD) and clinical attachment level (CAL).  
The plaque index score was significantly higher in Group II (2.20±0.34) and 
Group III (2.29±0.37) when compared to Group I (0.25±0.23) (table 7 ; fig.4). PI 
score shows negative correlation with SOD level in all Groups but shows positive 
correlation in Group III, though the correlation was not significant. (table 20 ). 
The GBI was significantly higher in Group II (86.55±6.73) as compared to 
Group III (29.613±10.86) and both these Groups scores were significantly higher as 
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compared to Group I (15.37±7.81) with a p value >0.01.(table 8; fig.5).The post-
treatment values of Group IIA1 (15.70±3.2) Group IIB1 (13.15±2.55), Group III A1 
(12.65±2.36) and Group III B1 (15.15±2.92) were significantly reduced as compared 
to the pre-treatment value of Group II A (83.94±4.47), Group II B (84.71±8.18), 
Group III A (27.70±10.5) and Group III B (31.52±11.2) respectively (table 10, 11, 12 
& 13; fig.5).The post-treatment values were almost to the level of Group I 
(15.37+7.81) GBI score (table 16, 17, 18 & 19).The GBI score shows negative 
correlation with SOD level of all Groups, but shows positive correlation in Group II 
and Group IIB1, though all were not significant with p value >0.05. (table 20&21; fig. 
9,12,15,18,21,24,27,30&33 ). 
The PD was significantly higher in Group II (4.87±0.81) and Group III 
(4.82±0.76) as compared to Group I (1.64±0.29) with a p value <0.01. (table 8, 
fig.6).There was no significant difference in PD between Group II (4.87±0.81) and 
Group III (4.82±0.76) with a p value 0.798 (table 9; fig. 6 ).The post treatment values 
of Group IIA1 (3.26±0.33) Group IIB1(3.38±0.52), Group III A1 (3.29±0.513) and 
Group III B1 (3.412±0.37) were significantly reduced as compared to the pre-
treatment value of Group IIA (4.96±0.75), Group IIB (4.79±0.87), Group III A 
(4.526±0.73) and Group IIIB  (5.124±0.63) respectively (table 10,11,12&13; fig.6). 
There was negative correlation between PD and SOD level of all Groups, but shows 
positive correlation in Group II. The correlation was significant only in Group IIIA1. 
(table 20&21; fig. 10,13,16,19,22,25,28,31&34 ). 
No loss in CAL was observed in Group I. There was no significant difference 
in CAL between Group II(5.10±0.742) and Group III(5.150±0.75)  with a p value 
0.802.(table 9, fig.7). The post treatment values of Group IIA1 (3.44±0.47), Group 
IIB1 (3.62±0.59), Group III A1 (3.55±0.55) and Group IIIB1 (3.82±0.54) were 
_____________________________________________________________________________Results 
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significantly reduced as compared to the pre-treatment value of Group IIA 
(5.14±0.54), Group IIB (5.06±0.92), Group III A (4.85±0.61) and Group IIIB 
(5.46±0.76) respectively (table 10, 11, 12 and 13; fig.7). There  was negative 
correlation between CAL and SOD level of all Groups, but shows positive correlation  
in Group II and Group IIIB1. The correlation was significant only in Group IIIA1 
(table 20&21; fig. 11,14,17,20,23,26,29,32&35 )..  
LABORATORY FINDINGS OF SALIVARY SUPEROXIDE DISMUTASE LEVEL 
The baseline salivary SOD level was significantly less in Group II (25±3.99) 
and Group III (13.75±2.84)  compared to control Group (149.2± 10.2) , p value <0.01 
(table 8; fig.8). The mean SOD of Group III (13.75±2.84) was significantly less as 
compared to Group II (25±3.99)  with a p value <0.01 (table.9; fig.8) . 
There was no significant difference in the pre treatment level of SOD in Group 
II A (25.5±4.03) and Group III A (13.33±2.43) to the post-treatment level in Group II 
A1 (25.67±3.94) and Group IIIA1 (13.83±2.96) respectively (table 10,12; fig.8). SOD 
level significantly increased in post-treatment of Group II B1 (67±12.47) and Group 
III B1 (30.37±7.49) as compared to pre-treatment of Group II B (24.5±4.03) and 
Group III B (14.17±3.23) respectively (table 11,13;fig.8). 
There was a significant difference in the post treatment level of SOD of Group 
IIA1 (25.67±3.94) as compared to Group II B1 (67±12.47) with a p value <0.01(table 
14 ).There was a significant difference in the post treatment level of SOD between 
Group III A1 (13.83±2.96) and Group III B1 (30.37±7.49) with p value <0.01 
(table15). The post treatment level of SOD had increased in GroupIIB1 (67±12.47) 
and Group III B1  (30.37±7.49) but not to the level of periodontally healthy controls 
(149.2± 10.2) (table17,19). 
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 Table 1: MASTER CHART 1 GROUP I (CONTROL) 
SNO AGE PI GBI (%) PPD(mm) CAL(mm) SOD (U/ml) 
1 35 0.48 14.3 1.85 0 135 
2 47 0.74 28 1.94 0 147.5 
3 38 0.26 16.7 2.1 0 160 
4 40 0.4 22.3 1.86 0 152.5 
5 40 0.11 11 1.45 0 137.5 
6 55 0.19 10 1.6 0 142.5 
7 43 0.09 12 1.42 0 155 
8 37 0.05 18 1.42 0 140 
9 39 0.02 0 1.14 0 165 
10 41 0.12 21.4 1.65 0 157.5 
 
Table 2: MASTER CHART 2 GROUP IIA (NON SMOKERS- SRP ALONE) 
S.NO AGE PI1 GBI1 
(%) 
PPD1 
(mm) 
CAL1 
(mm) 
SOD1 
(U/ml) 
GBI2 
(%) 
PPD2 
(mm) 
CAL2 
(mm) 
SOD2 
(U/ml) 
1 39 2.6 85.2 5.53 5.53 35 10.94 3.05 3.05 35 
2 45 2.03 89 4.9 4.9 30 18.3 3.29 3.29 30 
3 50 1.84 89 5.43 5.52 22.5 15.6 3.17 3.22 25 
4 38 1.85 81.9 3.03 4.79 27.5 15.83 3.24 3.24 27.5 
5 39 2.13 92.18 4.95 5.06 25 15.62 3.11 3.33 25 
6 35 2.47 89.1 4.35 4.49 27.5 13.28 3.14 3.24 27.5 
7 44 2.25 95 4.4 4.4 22.5 17.6 3.21 3.21 22.5 
8 48 1.91 94.2 4.5 4.6 25 19.2 3.24 3.24 25 
9 54 1.85 84.25 5.2 5.2 25 20.4 4.29 4.69 25 
10 40 1.69 83.3 5.5 5.7 27.5 13.5 3.53 4.08 27.5 
11 45 2.69 89.13 5.67 5.67 22.5 7.6 3.44 4.12 22.5 
12 50 2.29 84.4 4.59 4.59 17.5 18 3.15 3.15 17.5 
13 53 1.85 83.2 5.14 5.14 25 16.6 3.34 3.38 25 
14 52 2.44 94.53 4.91 5.12 27.5 17.2 2.9 3 27.5 
15 43 1.88 91.53 6.33 6.33 22.5 15.89 2.88 3.38 22.5 
42 
 
Table 3: MASTER CHART 3 GROUP IIB (NON SMOKERS- SRP+ VITAMIN C) 
 
S. NO AGE  PI1 GBI1 
(%) 
PPD1 
(mm) 
CAL1 
(mm) 
SOD1 
U/ml 
GBI2 
(%) 
PPD2 
(mm) 
CAL2 
(mm) 
SOD2 
U/ml 
1 38 2 75 6.21 6.74 22.5 13.6 3.88 4.17 80 
2 40 2.11 90 6.38 6.71 25 12 3.96 4.23 52.5 
3 35 2 89.6 4.89 5.1 22.5 10.4 3.12 3.4 57.5 
4 38 2.01 91.3 5.34 5.34 27.5 13 3.08 3.08 60 
5 54 2.05 95.16 4.87 5.06 20 13.7 3.81 4.07 67.5 
6 45 2.11 74.2 4.06 4.3 30 12 2.67 2.7 72.5 
7 42 2.33 90 4.3 4.57 25 15 3.58 3.79 57.5 
8 44 2.7 78 4.75 5.11 22.5 14 3.23 4.1 92.5 
9 34 2.46 93 4.15 4.8 17.5 17.1 4.1 4.2 62.5 
10 47 2.34 93 5.67 6.13 27.5 10.34 4.09 4.51 50 
11 52 2.4 72 3.93 4.07 20 17 2.98 3.02 77.5 
12 35 2.92 79.68 4.18 4.44 25 7.8 3.07 3.11 55 
13 45 2.96 75 3.33 3.56 22.5 12.06 2.46 2.74 82.5 
14 54 1.93 90.62 4.43 4.53 32.5 13.39 3.71 3.72 62.5 
15 51 2.03 84.1 5.38 5.55 27.5 16 3.04 3.4 75 
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Table 4: MASTER CHART 4 GROUP IIIA (SMOKERS- SRP ALONE) 
 
S. NO AGE PI GBI1 
(%) 
PPD1 
(mm) 
CAL1 
(mm) 
SOD1 
U/ml 
GIB2 
(%) 
PPD2 
(mm) 
CAL2 
(mm) 
SOD2 
U/ml 
1 49 2.11 16 4.07 4.4 12.5 14 2.67 2.7 15 
2 52 2.33 16.7 4.2 4.57 10 12 3.58 3.78 10 
3 40 2.7 28.12 4.7 5.11 15 14 3.8 3.79 15 
4 37 2.4 18.5 4.1 4.8 12.5 14 4 4.2 12.5 
5 58 2.3 43.1 5.6 6.13 10 12 4.4 4.9 10 
6 49 2.96 18.2 3.34 4 17.5 12 2.4 3 20 
7 45 2.82 39.6 4.18 4.44 15 7.8 3 3.2 15 
8 35 2.96 18.2 3.34 4 17.5 12 2.4 3 17.5 
9 49 2.93 40 4.34 4.53 15 13.28 3.72 3.9 17.5 
10 39 2.3 43 5.38 5.4 15 16 3.7 3.8 12.5 
11 38 2.6 35.2 5.33 5.33 12.5 11 3.05 3.55 12.5 
12 39 2.03 18.9 4.9 5.11 12.5 8.3 3.29 3.5 12.5 
13 42 1.84 29 5.43 5.52 12.5 15.6 3.17 3.17 15 
14 40 1.85 33 4.03 4.19 10 15 3.2 3.5 10 
15 35 2.13 18 4.95 5.02 12.5 13 3.11 3.28 12.5 
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Table 5: MASTER CHART 5 GROUP IIIB (SMOKERS- SRP + VITAMIN C) 
 
 
S. NO AGE  PI GBI 
(%) 
PPD 
(mm) 
CAL 
(mm) 
SOD1 
U/ml 
GBI2 
(%) 
PPD2 
(mm) 
CAL2 
(mm) 
SOD2 
U/ml 
1 45 2.47 52 4.35 4.49 12.5 13.28 3.14 3.24 25 
2 35 2.25 24 4.4 4.4 15 17.6 3.21 3.21 22.5 
3 38 1.91 40 4.5 4.6 12.5 19.2 3.34 3.24 32.5 
4 43 1.85 25 5.2 5.8 10 20.4 4.29 4.69 22.5 
5 47 1.69 33.33 5.5 5.5 15 13.5 3.53 4.8 27.5 
6 39 2.68 49.13 5.67 6.3 12.5 17.6 3.44 4.2 35 
7 46 2.29 24.4 4.32 5 17.5 18 3.15 3.62 32.5 
8 53 2.85 38.7 5 5.32 10 16.67 3.34 3.88 25 
9 38 2.44 14.53 4.91 5.12 12.5 10.2 2.9 3.4 30 
10 37 1.88 41.34 5.33 6.2 10 14.89 3.12 3.38 20 
11 53 2 25 6.21 6.74 15 13.63 3.88 4.17 25 
12 48 2.11 20 6.38 6.71 15 14 3.96 4.23 37.5 
13 37 2 39 4.89 5.1 20 12 3.48 4 45 
14 48 2 21.3 5.34 5.61 15 12.32 3.08 3.23 32.5 
15 35 2.06 25.16 4.87 5.06 20 14 3.33 4.07 43 
 
 
 
 
 
 
45 
 
Table 6: COMPARISON OF AGE BETWEEN GROUP I,II AND III 
Age  
(in 
years) 
Group I Group II Group III P value 
Mean  SD Mean  SD Mean  SD 0.447 
41.5 5.77 44.3 6.417 42.96 6.44 
Statistical Analysis: one way ANOVA 
 
Table 7: COMPARISON OF PLAQUE INDEX BETWEEN GROUP I, II & III 
 
Plaque  
Index 
Group I Group II Group III P value 
Mean  SD Mean  SD Mean  SD 0.00
** 
0.246 0.229 2.204 0.335 2.291 0.376 
Statistical Analysis: one way ANOVA; **Significant at p<0.01                                                                                                                             
 
Table8: COMPARISON OF CLINICAL PARAMETERS AND SALIVARY 
SOD LEVEL BETWEEN GROUP I, II AND III 
     Group I Group II Group III Significance 
Mean S.D Mean S.D Mean S.D  
GBI (%) 15.37 7.812 86.55 6.73 29.613 10.862 0.00
** 
PD (mm) 1.6430 0.2941 4.87 0.805 4.825 0.736 0.00** 
CAL (mm) 0.00 0.00 5.10 0.742 5.150 0.747 0.00** 
SOD (U/ml) 149.2 10.277 25 3.993 13.75 2.842 0.00** 
  Statistical Analysis: one way ANOVA; **Significant at p<0.01                                                                                                                             
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Table 9: COMPARISON OF CLINICAL PARAMETERS AND SALIVARY 
SOD LEVEL BETWEEN GROUP II AND III 
 Group II Group III Significance 
Mean S.D Mean S.D  
GBI (%) 86.55 6.73 29.613 10.862 0.00
** 
PD (mm) 4.87 0.805 4.825 0.736 0.798 
CAL (mm) 5.10 0.742 5.150 0.747 0.802 
SOD (U/mI) 25 3.993 13.75 2.842 0.00** 
Statistical Analysis: Independent t Test; **Significant at p<0.01                                                                                                                             
   
 
Table 10: COMPARISON OF CLINICAL PARAMETERS AND SALIVARY 
SOD LEVEL BETWEEN GROUP II-A  AND GROUP II-A1 
 Group II – A GROUP II-A1 Significance 
Mean S.D Mean S.D  
GBI (%) 8.394 4.467 15.704 3.2 0.00** 
PD (mm) 4.962 0.759 3.265 0.332 0.00** 
CAL (mm) 5.136 0.5386 3.441 0.472 0.00** 
SOD (U/mI) 25.5 4.03 25.667 3.94 0.337 
Statistical Analysis: Paired t test; **Significant at p<0.01                                                                                                                             
 
Table 11: COMPARISON OF CLINICAL PARAMETERS AND SALIVARY 
SOD LEVEL BETWEEN GROUP II-B  AND GROUP II-B1 
 Group II - B GROUP II-B1 Significance 
Mean S.D Mean S.D  
GBI (%) 84.71 8.177 13.15 2.55 0.00** 
PD (mm) 4.791 0.867 3.385 0.524 0.00** 
CAL (mm) 5.067 0.9177 3.616 0.591 0.00** 
SOD (U/mI) 24.5 4.03 67 12.47 0.00** 
Statistical Analysis: Paired t test; **Significant at p<0.01                                                                                                                             
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Table12: COMPARISON OF CLINICAL PARAMETERS AND SALIVARY 
SOD LEVEL BETWEEN GROUP III-A  AND GROUP III-A1 
 Group III- A GROUP III-A1 Significance 
Mean S.D Mean S.D  
GBI (%) 27.701 10.50 12.65 2.364 0.00** 
PD (mm) 4.526 0.727 3.299 0.513 0.00** 
CAL (mm) 4.836 0.6103 3.551 0.548 0.00** 
SOD (U/mI) 13.33 2.43 13.833 2.96 0.189 
Statistical Analysis: Paired t test; **Significant at p<0.01                                                                                                                             
 
Table13: COMPARISON OF CLINICAL PARAMETERS AND SALIVARY 
SOD LEVEL BETWEEN GROUP III-B  AND GROUP III-B1 
 Group III – B GROUP III-B1 Significance 
Mean S.D Mean S.D  
GBI (%) 31.52 11.2 15.15 2.92 0.00** 
PD (mm) 5.124 0.634 3.412 0.374 0.00** 
CAL (mm) 5.4633 0.757 3.824 0.538 0.00** 
SOD (U/mI) 14.1667 3.227 30.366 7.491 0.00** 
Statistical Analysis: Paired t test; **Significant at p<0.01                                                                                                                             
 
Table14: COMPARISON OF SALIVARY SOD LEVEL BETWEEN GROUP II-
A1 AND GROUP II-B1 
 GROUP II-A1 GROUP II-B1 Significance 
 Mean S.D Mean S.D  
SOD 
(U/mI) 
25.66 3.94 67 12.471 0.00** 
Statistical Analysis: Independent t Test; **Significant at p<0.01                                                                                                                             
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Table15: COMPARISON OF SALIVARY SOD LEVEL  BETWEEN  GROUP 
III-A1 AND GROUP III-B1 
 GROUP III-A1 GROUP III-B1 Significance 
 Mean S.D Mean S.D  
SOD (U/mI) 13.833 2.968 30.667 7.491 0.00
** 
            Statistical Analysis: Independent t Test; **Significant at p<0.01                                                                                                                             
 
Table16: COMPARISON OF CLINICAL PARAMETERS AND SALIVARY 
SOD LEVEL BETWEEN GROUP I AND GROUP II-A1 
Values GROUP I GROUP II-A1 P value 
Mean SD Mean SD 
GBI(%) 15.3700 7.81211 15.7040 3.2960 0.018 
PPD (mm) 1.6430 .29413 3.2653 .3329 .754 
CAL (mm) 0.0000 0.0000 3.4413 0.4726 0.002** 
SOD (U/ml) 149.25 10.277 25.666 3.949 0.000
** 
             Statistical Analysis: Independent t Test; **Significant at p<0.01                                                                                                                             
 
Table17: COMPARISON OF CLINICAL PARAMETERS AND SALIVARY 
SOD LEVEL BETWEEN GROUP I AND GROUP II-B1 
Values GROUP I GROUP II-B1 P value 
Mean SD Mean SD 
GBI (%) 
 
15.3700 7.81211 13.1593 2.55218 0.006 
PPD (mm) 1.6430 .29413 3.3853 .52403 .0130 
CAL (mm) 0.0000 0.0000 3.6160 0.59185 0.000
** 
SOD (U/ml) 149.25 10.277 67 12.47140 0.460 
             Statistical Analysis: Independent t Test; **Significant at p<0.01                                                                                                                             
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Table18: COMPARISON OF CLINICAL PARAMETERS AND SALIVARY 
SOD LEVEL BETWEEN GROUP I AND GROUP III-A1 
 
Values GROUP I GROUP III-A1 P value 
Mean SD Mean SD 
GBI (%) 15.3700 7.81211 12.6653 2.36475 .004** 
PPD (mm) 1.6430 .29413 3.2993 .57304 .065 
CAL (mm) 0.0000 0.0000 3.5513 .54855 .001** 
SOD (U/ml) 149.25 10.277 13.8333 2.96808 .000** 
             Statistical Analysis: Independent t Test; **Significant at p<0.01                                                                                                                             
 
 
Table19: COMPARISON OF CLINICAL PARAMETERS AND SALIVARY 
SOD LEVEL BETWEEN GROUP I  AND GROUP III-B1 
 
Values GROUP I GROUP III-B1 P value 
Mean SD Mean SD 
GBI (%) 15.3700 7.81211 15.1527 2.92866 .014 
PPD (mm) 1.6430 .29413 3.4127 0.37490 .615 
CAL (mm) 0.0000 0.0000 3.8240 .53809 .000** 
SOD (U/ml) 149.25 10.277 30.3667 7.49158 .137 
             Statistical Analysis: Independent t Test; **Significant at p<0.01                                                                                                                             
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Table20:  CORRELATION BETWEEN THE SALIVARY SODS LEVEL AND 
THE CLINICAL PARAMETERS OF GROUP I, II AND III 
SOD (U/ml)  PI GBI(%) PPD(mm) CAL (mm) 
Group I 
 
 
Pearson 
correlation 
-0.248 -0.164 -0.087 0 
Sig 2 tailed 0.490 0.651 0.810 0 
Group II 
 
Pearson 
correlation 
-0.140 0.024 0.072 0.069 
Sig 2 tailed 0.462 0.900 0.706 0.717 
Group III  
 
 
Pearson 
correlation 
0.159 -0.150 -0.166 -0.184 
Sig 2 tailed 0.403 0.430 0.381 0.330 
 
Table21:  CORRELATION BETWEEN THE SALIVARY SODS LEVEL AND 
THE CLINICAL PARAMETERS OF GROUP I, II AND III 
SOD(U/ml)  GBI(%) PPD(mm) CAL(mm) 
Group IIA 
 
 
Pearson 
correlation 
-0.243 -0.061 -0.152 
Sig 2 tailed 0.382 0.828 0.589 
Group II B 
 
 
Pearson 
correlation 
0.420 -0.448 -0.230 
Sig 2 tailed 0.119 0.094 0.409 
Group IIIA 
 
 
Pearson 
correlation 
-0.060 -0.577 -0.541 
Sig 2 tailed 0.831 0.024 0.037 
Group III B 
 
 
Pearson 
correlation 
-0.293 -0.013 0.148 
Sig 2 tailed 0.289 0.962 0.600 
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Figure 3 : Comparison of Age (in years) between Group I , Group II and 
Group III 
 
 
Figure 4 : Comparison of Plaque Index between Group I , Group II and  
Group III 
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Figure 5 : Comparison of Gingival Bleeding Index between Group I ,    
   Group II A, Group II B , Group III A and Group III B 
 
 
Figure 6 : Comparison of Probing Depth(in mm)  between Group I ,    
 GroupIIA, Group II B, Group III A and Group III B 
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      Figure 7 : Comparison of Clinical Attachment Level (in mm) between            
 Group I , Group II A , Group II B, Group III A and Group III B 
 
 
 Figure 8 : Comparison of SOD Levels between GroupI , GroupII A       
      Group II B, Group III A and Group III B 
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Figure 9 : Correlation Of Salivary SOD Levels And Gingival Bleeding       
Index In Group I
 
 
 
Figure 10 : Correlation Of Salivary SOD Levels And Probing Depth          
 in Group I   
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Figure 11 : Correlation Of Salivary SOD Levels And Clinical Attachment 
     Level In Group I 
 
 
 
Figure 12 : Correlation Of Salivary SOD Levels And Gingival Bleeding 
Index In  Group II A (Pre therapy) 
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Figure 13 : Correlation Of Salivary SOD Levels And Probing Depth In 
          Group II A (Pre therapy) 
 
 
Figure 14 : Correlation Of Salivary SOD Levels And Clinical Attachment 
      Level In  Group II A (Pre therapy) 
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Figure 15 : Correlation Of Salivary SOD Levels And Gingival Bleeding 
    Index In Group II B (Pre therapy) 
 
 
 
Figure 16 : Correlation Of Salivary SOD Levels And Probing Depth In 
          Group II B (Pre therapy) 
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Figure 17 : Correlation Of Salivary SOD Levels And Clinical Attachment 
   Level  In Group II B (Pre therapy) 
 
 
 
Figure 18 : Correlation Of Salivary SOD Levels And Gingival Bleeding 
   Index In Group III A(Pre therapy) 
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Figure 19 : Correlation Of Salivary SOD Levels And Probing Depth In 
             Group III A (Pre therapy) 
 
 
 
Figure 20 : Correlation Of Salivary SOD Levels And Clinical Attachment 
  Level In Group III A (Pre therapy) 
 
60 
 
 
Figure 21 : Correlation Of Salivary SOD Levels And Gingival Bleeding 
   Index In Group III B (Pre therapy) 
 
 
 
Figure 22 : Correlation Of Salivary SOD Levels And Probing Depth In 
          Group III B (Pre therapy) 
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Figure 23 : Correlation Of Salivary SOD Levels And Clinical Attachment 
   Level In Group III B (Pre therapy) 
 
 
 
Figure 24 : Correlation Of Salivary SOD Levels And Gingival Bleeding 
   Index In Group II A (Post therapy) 
 
62 
 
 
Figure 25 : Correlation Of Salivary SOD Levels And Probing Depth In 
          Group II A  (Post therapy) 
 
 
Figure 26 : Correlation Of Salivary SOD Levels And Clinical Attachment 
   Level In Group II A (Post therapy) 
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Figure 27 : Correlation Of Salivary SOD Levels And Gingival Bleeding 
   Index In Group II B (Post therapy) 
 
 
 
Figure 28 : Correlation Of Salivary SOD Levels And Probing Depth In 
          Group II B  (Post therapy) 
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Figure 29 : Correlation Of Salivary SOD Levels And Clinical Attachment                
Level In Group II B (Post therapy) 
 
 
 
Figure 30 : Correlation Of Salivary SOD Levels And Gingival Bleeding 
   Index In Group III A (Post therapy) 
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Figure 31 : Correlation Of Salivary SOD Levels And Probing Depth In 
          Group III A  (Post therapy) 
 
 
Figure 32 : Correlation Of Salivary SOD Levels And Clinical Attachment 
   Level In Group III A (Post therapy) 
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Figure 33 : Correlation Of Salivary SOD Levels And Gingival Bleeding 
   Index In Group III B (Post therapy) 
 
 
 
Figure 34 : Correlation Of Salivary SOD Levels And Probing Depth In 
          Group III B  (Post therapy) 
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Figure 35 : Correlation Of Salivary SOD Levels And Clinical Attachment 
   Level In Group III B (Post therapy) 
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DISCUSSION 
Recently there is  categorical evidence in the literature to identify smoking as 
a major risk factor for periodontitis
15,70
. Also there has been increasing interest in 
ROS and antioxidant system in the etiology of periodontitis.
29,33 
However, the exact mechanism how smoking exerts its destruction on 
periodontium is still unclear. It has been attributed that there is induction of oxidative 
stress by nicotine which may lead to depletion of antioxidants and this has been 
considered as one of the mechanisms for periodontal tissue damage. 
Many studies in the periodontal field have been carried out in GCF, serum and 
very recently in saliva to find out antioxidant conditions of periodontitis patients. In 
this study whole saliva was used as sampling medium. In contrast to GCF whole 
saliva is a pool of all diseased sites of oral cavity and method of collection is non-
invasive as well as easy to perform.
64 
The main finding in the present study was, baseline salivary SOD level 
significantly reduced in smokers than non-smokers with chronic periodontitis (ChP) 
as compared to control group. There was a significant reduction in all clinical 
parameters in smokers and non-smokers with ChP one month following SRP. Salivary 
SOD level significantly increased (p<0.01)in smokers and non-smokers with ChP one 
month following SRP supplemented with vitamin C.  
  In the present study at baseline, all the clinical parameters namely PI, GBI, PD 
and CAL were significantly higher in non-smokers and smokers with ChP as 
compared to the periodontally healthy controls (p value <0.01) (table 8). There was 
___________________________________________________________________________Discussion 
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negative correlation between salivary SOD and all clinical parameters in group I 
(table 20).  
 The baseline gingival bleeding index was significantly reduced (p <0.01) in 
smokers with ChP group  as  compared to non-smokers with ChP group but GBI score 
was significantly higher in both the groups than control group with a p value <0.01 
(table 8 and  9). This finding is in accordance with the concept that, smokers 
generally present with reduced gingival inflammation and bleeding on probing as 
compared to non-smokers, because of strong, chronic, dose-dependent suppressive 
effect of smoking on gingival inflammation and bleeding as documented in the Third 
National Health and Nutritional Examination Survey (NHANES III). This is also in 
agreement with findings of Nair P et al 2003 who emphasised the effect of smoking 
in masking the signs and symptoms of inflammation in periodontal disease.
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SOD is an intrinsic AO as well as a primary defending substance that protects 
cells from ROS by converting superoxide anion into H2O2. Several studies have 
examined the relationship between SOD and periodontitis.
4,13,64
     
The present study shows statistically significant difference (p value <0.01) in 
baseline salivary SOD level in control, non-smokers and smokers with ChP. Salivary 
SOD level was observed to be least in smokers with ChP while it is maximum in 
healthy controls (table 8). This finding is concurrent with  Agnihotri R 2009  who 
concluded that a progressive reduction in SOD levels in saliva and GCF in healthy 
non smokers to light smokers to heavy smokers with ChP.
2
 Garg et al 2006 concluded 
that  SOD levels were higher in non-smokers than smokers both in tissue and blood 
and his finding is similar to the findings of the present study.
30 
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The reason for the decreased salivary SOD level may be due to increased 
oxidative stress and nicotine in smokers that had caused the depletion of antioxidant 
enzymes and also by negative feedback inactivation of SOD due to over production of 
hydrogen peroxide.
2 
Chronic periodontitis is primarily a gram negative infection caused by putative 
periodontal pathogens resulting in immune-inflammatory response. Since SRP is the 
corner stone of periodontal therapy to reduce the bacterial burden, in the present study 
SRP is being opted as treatment modality. 
Vitamin C is an essential dietary vitamin which cannot be synthesised by 
human cells. It is an electron donor and this property accounts for its antioxidant 
function. It is a co-factor for many enzymes and has the ability to regenerate other 
antioxidants.
8 
Since ROS plays an important role in the pathogenesis of periodontitis, 
many antioxidants have been supplemented in recent researches to evaluate its 
effectiveness in periodontal treatment.
6,8 
In the present study we have supplemented 500mg vitamin C in tablet form 
once daily from the day of SRP for one month to evaluate whether it has any 
additional effect in improving the antioxidant level by measuring salivary SOD. 
In the present study, after one month of treatment the gingival bleeding index, 
probing depth and clinical attachment level were significantly reduced in non-smokers 
(group II) and smokers (group III) with ChP (tables 10, 11, 12 and 13). There was no 
significant difference in the clinical parameters after one month of treatment between 
non-smokers group IIA and smokers group IIIA (with SRP alone)  as compared to 
non-smokers group IIB and smokers group IIIB (with SRP  and vitamin C) (tables 14 
and 15) 
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This implies that the adjunctive dose of vitamin C in group IIB and group IIIB 
did not offer any additional effect in regard to clinical parameters. This is in 
accordance with Ali E et al 2010 who evaluated the effect of vitamin C as adjunct to 
SRP in chronic periodontitis subjects and concluded that there was no significant 
difference in post treatment clinical parameter between SRP group as compared to 
group with SRP and vitamin C.
8. 
This is in concurrence to the findings of Leggott et al  
who did not find a relationship between PD and BOP measures and the concentration 
of ascorbic acid in periodontitis subjects  after using a dose of vitamin C  as an 
adjunct to non-surgical periodontal treatment.
44 
In the present study, salivary SOD level shows no significant difference 
between the baseline and post-treatment value in non-smokers (group IIA) and 
smokers (group III A) with SRP alone (tables 10 and 12). This finding of the present 
study is in contrast to Kim et al 2010 who compared the total antioxidant status (TAS) 
and superoxide dismutase (SOD) activity in the saliva of periodontally compromised 
patients before and after scaling and root planing (SRP) therapy and concluded that 
the SOD activity had increased at 3 months after SRP
42
. This variation in findings 
may be due to the difference in the time of post-treatment sampling in our study as 
compared to the above mentioned study.  
The salivary SOD levels significantly increased (P<0.01) after one month of 
vitamin C supplementation alongwith SRP in Group II B and Group III B (tables 11 
and 13). However, this increase in SOD levels after treatment were still less  
compared to periodontally healthy controls (tables 17 and 19).  
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SUMMARY AND CONCLUSION 
In the present study 70 male subjects were recruited to evaluate and compare 
the salivary SOD level in smokers and non-smokers with chronic periodontitis before 
and after SRP with vitamin C as an adjunct. 
From the results of this study the following conclusion can be drawn: 
1. Baseline salivary SOD level in smokers with chronic periodontitis is less 
compared to periodontally healthy controls. 
2. Baseline salivary SOD level in smokers with chronic periodontitis is less 
compared to non-smokers with chronic periodontitis. 
3. SRP in smokers and non-smokers with chronic periodontitis does not affect 
the salivary SOD level after one month. 
4. Adjunctive dose of vitamin C has improved salivary SOD level in smokers 
and non-smokers with chronic periodontitis than SRP alone. 
In the periodontal literature it has been hypothesized that deficiency of vitamin C 
has been considered as a risk factor in the pathogenesis of periodontitis. Here in the 
present study vitamin C supplementation had resulted in a significant improvement in 
salivary antioxidant status in subjects with chronic periodontitis. Further longitudinal 
studies may be needed for the administration of vitamin C as an adjunct to periodontal 
therapy in order to maintain a stable periodontium.  
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ANNEXURE : 1 
 
INFORMATION SHEET 
 
We are conducting a study on evaluation of effectiveness of vitamin C following 
phase I therapy by estimating salivary superoxide dismutase level in smokers 
with chronic periodontitis 
The identity of the patients participating in the research will be kept confidential 
throughout the study. In the event of any publication or presentation resulting from 
the research, no personally identifiable information will be shared. 
 Taking part in the study is voluntary. You are free to decide whether to 
participate in the study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
 
 
Name of the patient               Signature / Thumb impression  
 
 
 
 
Name of the investigator              Signature  
 Date 
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ANNEXURE : 2 
 
INFORMED CONSENT FORM 
 
EVALUATION OF EFFECTIVENESS OF VITAMIN C FOLLOWING PHASE I THERAPY BY 
ESTIMATING SALIVARY SUPEROXIDE DISMUTASE LEVEL IN SMOKERS WITH 
CHRONIC PERIODONTITIS 
Name:     Age / Sex:      O.P.No   
                                       : 
Address:                                                                  
I, ___________________________________________________age____years 
exercising my free power of choice, hereby give my consent to be included as a 
participant in the study evaluation of effectiveness of vitamin C following phase I 
therapy by estimating salivary superoxide dismutase level in smokers with chronic 
periodontitis I agree to the following:  
 I have been informed to my satisfaction about the purpose of the study and 
study procedures including investigations to monitor and safeguard my body 
function. 
 I agree to co-operate fully and to inform my doctor immediately if I suffer 
any unusual symptom. 
 I have informed the doctor about all medications I have taken in the recent 
past and those I am currently taking. 
 I hereby give permission to use my medical records for research purpose. I 
am told that the investigating doctor and institution will keep my identity 
confidential 
 
 
Name of the patient   Signature / Thumb impression 
 
Name of the investigator   Signature       
Date 
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ANNEXURE : 3 
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ANNEXURE : 4 
 
EVALUATION OF EFFECTIVENESS OF VITAMIN C FOLLOWING PHASE 
I THERAPY BY ESTIMATING SALIVARY SUPEROXIDE DISMUTASE 
LEVEL IN SMOKERS WITH CHRONIC PERIODONTITIS 
PROFORMA 
Name  :      Age / Gender: 
 
O.P. No :       Code No: 
 
Occupation :      Income    : 
 
Address and Contact No.:              
 
 
Chief Complaints 
Duration: 
Medical history 
Dental history 
Habits: 
 
Periodontal Examination:                
 
                                              PLAQUE INDEX – SILNESS & LOE (1964) 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
Score:  
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GINGIVAL BLEEDING INDEX – AINAMO & BAY (1975) 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
Score: 
 
 PROBING DEPTH  & CLINICAL ATTACHMENT LEVEL  (in mm) 
MAXILLARY:    
     Palatal 
CAL                 
PPD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PPD                 
CAL                 
     Buccal 
MANDIBULAR: 
     Lingual 
CAL                 
PPD                 
 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
PPD                 
CAL                 
     Buccal 
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DIAGNOSIS: 
INVESTIGATIONS: 
OPG 
SALIVARY SOD LEVEL 
TREATMENT  
 
AFTER THERAPY (after 1 month) 
 
GINGIVAL BLEEDING INDEX – AINAMO & BAY (1975) 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
Score:  
 
 
                  PROBING DEPTH  & CLINICAL ATTACHMENT LEVEL  (in mm) 
MAXILLARY:    
                                                                  Palatal 
CAL                 
PPD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PPD                 
CAL                 
     Buccal 
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MANDIBULAR: 
     Lingual 
CAL                 
PPD                 
 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
PPD                 
CAL                 
     Buccal 
INVESTIGATION: 
SALIVARY SOD LEVEL: 
 
INFERENCE: 
 
 
Signature of the P.G student    Signature of Guide 
 
Date    
